试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-01
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
编号:NCT04920383登记状态:提前终止企业 / 申办者:Alpine Immune Sciences, Inc.
药物 / 成分:ALPN-202、pembrolizumab KEYTRUDA®
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-01
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
编号:NCT05099549登记状态:提前终止企业 / 申办者:NKGen Biotech, Inc.
药物 / 成分:AFM24、SNK01
登记的停止原因(原文):Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-01
Wound Healing Following Penile Prosthesis Implant
编号:NCT05196191登记状态:提前终止企业 / 申办者:VIVEX Biologics, Inc.
药物 / 成分:VIAGENEX Max、Hibiclens wash
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-29
The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy
编号:NCT02252432登记状态:提前终止企业 / 申办者:Cedars-Sinai Medical Center
药物 / 成分:Ketamine、Methadone、Ketamine + methadone
登记的停止原因(原文):No enough recruitments, very slow enrollment over the years
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-29
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
编号:NCT03711279登记状态:提前终止企业 / 申办者:Jiangsu HengRui Medicine Co., Ltd.
药物 / 成分:SHR-1210 plus Apatinib、ADM plus IFO or IFO alone
登记的停止原因(原文):Sponsor R \& D Strategy Adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-29
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
编号:NCT03718533登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Eltrombopag
登记的停止原因(原文):In the context of COVID-19 pandemic, the benefit / risk ratio of the participation of a patient with pancytopenia could be compromised. The decision of this premature termination was not the consequence of any safety reason inherent to the drug.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-29
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
编号:NCT04237116登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Investigational Arm - secukinumab、Control Arm - placebo
登记的停止原因(原文):Low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
编号:NCT00609154登记状态:提前终止企业 / 申办者:Albert Einstein College of Medicine
药物 / 成分:glucagon like peptide-1、glucose control
登记的停止原因(原文):Per source documents the study was terminated well in advance of targeted enrollment. A method for the analysis of insulin and proinsulin samples was never fully developed and validated. Study terminated upon expiration of IRB approval
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure
编号:NCT02857010登记状态:提前终止企业 / 申办者:Pere Gines
药物 / 成分:Allogenic mesenchymal stem cells、Placebo
登记的停止原因(原文):Dificulties to recruit patients and dificulties to obtain MSCs.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
编号:NCT03051516登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Laboratory Biomarker Analysis、Placebo Administration、Questionnaire Administration、Recombinant Human Papillomavirus Nonavalent Vaccine
登记的停止原因(原文):The study was terminated early due to futility.
查看官方原始记录 ↗